Dr. Lise Lund Kjems M.D., Ph.D. Net Worth

Dr. Lise Lund Kjems M.D., Ph.D. biography

Dr. Lise Lund Kjems M.D., Ph.D. is the Chief Medical Officer at Cyclo Therapeutics.

How old is Dr D?

Dr D is 57, he's been the Chief Medical Officer of Cyclo Therapeutics since . There are 5 older and 2 younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics, Inc. is George L. Fails, 76, who is the Exec. VP and Operations Mang..

What's Dr D's mailing address?

Lise's mailing address filed with the SEC is 91, Rollingwood Lane, Concord, Middlesex County, Massachusetts, 01742, United States.

Insiders trading at Cyclo Therapeutics

Over the last 4 years, insiders at Cyclo Therapeutics have traded over $0 worth of Cyclo Therapeutics stock and bought 4,648,141 units worth $6,142,223 . The most active insiders traders include Holdings, Inc. Rafael, Shawn Cross et N Scott Fine. On average, Cyclo Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $78,661. The most recent stock trade was executed by Holdings, Inc. Rafael on 1 August 2023, trading 4,000,000 units of CYTH stock currently worth $5,000,000.

What does Cyclo Therapeutics do?

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Cyclo Therapeutics executives and stock owners

Cyclo Therapeutics executives and other stock owners filed with the SEC include:

• N. Scott Fine,
  CEO & Director
• Dr. Sharon H. Hrynkow Ph.D.,
  Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Sr. VP of Medical Affairs
• Dr. Jeffrey L. Tate,
  COO, Chief Quality Officer & Director
• Dr. Lise Lund Kjems M.D., Ph.D.,
  Chief Medical Officer
• Lori McKenna Gorski,
  Global Head of Patient Advocacy
• Michael Eric Lisjak,
  Chief Regulatory Officer & Sr. VP of Bus. Devel.
• George L. Fails,
  Exec. VP and Operations Mang.
• Joshua M. Fine,
  CFO & Sec.
• C. E Strattan,
  Founder & Director
• Randall M. Toig,
  Director
• Shawn Cross,
  Director
• Vivien Wong,
  Director
• Holdings, Inc. Rafael,
  10% owner
• Francis Patrick Ostronic,
  Director
• William S Shanahan,
  Director
• Michael Eric Lisjak,
  Chief Regulatory Officer
• Sharon Hemond Hrynkow,
  Chief Scientific Officer
• N Scott Fine,
  Chief Executive Officer
• Joshua M Fine,
  Chief Financial Officer
• Jeffrey Tate,
  Chief Operating Officer
• Markus Sieger,
  Director
• Ce Rick Strattan,
  Director
• Lise Lund Kjems,
  Chief Medical Officer
• William Conkling,
  Director